US-based Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, has announced that its Optimer binder against cells associated with fibrotic liver disease, developed for targeted delivery of therapeutic payloads to fibrotic liver disease, has been shipped to a top 15 pharmaceutical companies for evaluation in their own therapeutic applications.
Aptamer Group, the developer of novel Optimer binders, has announced a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies. BaseCure Therapeutics is a pre-clinical stage biotech company dedicated to the discovery and development of innovative siRNA-based medicines. Aptamer is working with BaseCure Therapeutics to identify Optimer binders that identify specific cell types that might be developed as potential delivery vehicles for siRNA uptake into target cells and tissues.
Aptamer Group – a company which focuses on developing innovative novel binders across its Optimer-based platform – has revealed a new link-up with BaseCure Therapeutics. The partnership will primarily concentrate for the on emerging Optimer-targeted gene therapies.
Aptamer Group Appointment of Interim Chief Commercial Officer
Aptamer Group plc, a developer of novel Optimer binders to enable innovation in the life sciences industry, has opened its new facilities in York Science Park, UK, to meet increasing demand for Optimer technology.
Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, has negotiated a deal with the biotechnology company Flip Gene Therapeutics to support its novel, inducible gene therapy platform with the use of Optimer technology.
Aptar CSP Technologies, part of AptarGroup, Inc. and a provider of active material science solutions for product protection, extend shelf life and improve patient experience, announced its new manufacturing site is now able to produce its Activ-Blister Solutions for oral slide dose drugs in Europe. The move is part of a key strategic effort to expand production of Activ-Blister technology globally and is the result of a 3-way collaboration between Aptar CSP, Uhlmann, a pharmaceutical packaging equipment manufacturer, and Ivers-Lee, a local contract manufacturing organization.
Aptamer Group plc, a developer of novel Optimer binders to enable innovation in the life sciences industry, has extended its collaboration agreement with PinotBio, a clinical-stage oncology-focused biotechnology company, to develop four new Optimer-drug conjugates for use as precision chemotherapeutics.
Aptamer Group trades on AIM market of the London Stock Exchange
A British biotechnology firm that supplies big pharmaceutical firms with synthetic antibodies for targeted delivery of drugs will float in London this week valued at £80.7m – giving its two founders a combined paper fortune of more than £33m.